Close

BMO Capital Cuts Price Target on Applied Genetic Technologies (AGTC) to $20

Go back to BMO Capital Cuts Price Target on Applied Genetic Technologies (AGTC) to $20

AGTC Announces Financial Results and Business Update for the Quarter and Fiscal Year Ended June 30, 2016

September 12, 2016 4:22 PM EDT

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the quarter ended June 30, 2016.

Over the past year weve continued to make progress across our clinical programs and have remained focused on advancing novel gene-based therapies to improve the lives of patients affected by rare inherited diseases, said Sue Washer, President and CEO of AGTC. We are continuing to advance our... More